Project Grant R21CA313739
Award Date 6/10/26
Completion Date 5/31/28
Dollars Obligated $395K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Omaha, NE 68198, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded the Board of Regents of the University of Nebraska Medical Center a $651,038 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to advance understanding of tumor suppressive functions of Protein Phosphatase 2A (PP2A) in colorectal cancer treatment. The five-year project, which commenced May 1, 2026 and concludes April 30, 2031, funds fundamental and applied research into the development of small molecule...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Oklahoma Health Sciences Center a Project Grant totaling $407,726 under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of the zinc finger protein ZC3H15 in pancreatic cancer pathogenesis and therapeutic response. The award, effective June 15, 2026, through May 31, 2031, supports fundamental research to identify novel molecular regulators of pancreatic ductal adenocarcinoma...
- Federal Project Grant Award Summary The National Cancer Institute awarded $544,250 to the University of Nebraska Medical Center (UNMC) under the Cancer Treatment Research program (CFDA 93.395) for a five-year project running from August 4, 2025 through July 31, 2030. The award supports research investigating the immune drivers of persistent oncogenic human papillomavirus (HPV) infections in people living with HIV (PLWH), with an initial focus on oral HPV persistence as a precursor to...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $683,970 Project Grant to Columbia University's Health Sciences Division effective April 1, 2026 through March 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This research project focuses on developing and evaluating therapeutic approaches to treat pancreatic ductal adenocarcinoma (PDAC) through stromal modification and immune modulation. The research investigates the role of αvβ5 integrin in PDAC...
- Federal Grant Award Summary The National Cancer Institute awarded a $411,206 Project Grant to the University of California, San Diego under the Cancer Treatment Research program (CFDA 93.395) on May 14, 2026, with a completion date of April 30, 2028. This award supports the development of small molecule inhibitors targeting the proton-sensing receptor GPR68 for pancreatic ductal adenocarcinoma (PDAC) therapy. The research addresses a critical clinical need, as PDAC accounts for approximately 90%...
- Federal Project Grant Summary The National Cancer Institute (NCI) awarded $422,649 to the University of Illinois under the Cancer Biology Research program (CFDA 93.396) on June 1, 2026, to address racial disparities in acute myeloid leukemia (AML) treatment outcomes. The project, which extends through May 31, 2028, focuses on understanding why Black AML patients with mutant nucleophosmin (NPM1MUT) and wild-type FMS-like receptor tyrosine kinase (FLT3-WT) experience significantly worse...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $119,858 to the Regents of the University of Minnesota under the Cancer Biology Research program (CFDA 93.396) on August 7, 2025, for a project extending through July 31, 2030. This project grant supports fundamental research aimed at elucidating and overcoming T cell dysfunction in pancreatic ductal adenocarcinoma (PDA), a disease notoriously resistant to immunotherapy. The research program comprises three...
- Federal Grant Award Summary The National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded the University of Illinois a $412,249 Project Grant effective June 5, 2026, through May 31, 2028, to develop precision liver cancer modeling through CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) editing of primary human hepatocytes. The research addresses critical limitations in current hepatocellular carcinoma (HCC) models by creating a versatile platform that...
- Federal Grant Award Summary The National Cancer Institute awarded a $122,610 Project Grant to the University of Pennsylvania on August 11, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award, with a completion date of July 31, 2030, supports the development of a system to advance National Cancer Institute (NCI)-sponsored clinical trials for patients with rare gastrointestinal malignancies and rare disease populations. The project leverages the principal investigator's...
- Federal Grant Award Summary Purdue University received a $457,503 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on August 28, 2025, with completion targeted for July 31, 2030. The research project focuses on elucidating the posttranslational regulation of macropinocytosis in pancreatic ductal adenocarcinoma (PDAC), specifically investigating the role of protein phosphatase 2A (PP2A) subunit B56A in regulating nutrient-scavenging...